



## A Modern Take on Replicating Viral Vaccines

Guest Editors:

### **Dr. Markus Kainulainen**

Viral Special Pathogens Branch,  
Centers for Disease Control and  
Prevention (CDC), Atlanta, GA  
30329, USA

### **Dr. Anthony Griffiths**

National Infectious Diseases  
Laboratories, Boston University,  
Boston, MA, USA

Deadline for manuscript  
submissions:  
**closed (31 December 2022)**

### **Message from the Guest Editors**

Arguably the greatest accomplishments in curtailing viral diseases have been made possible by live-attenuated vaccines. Modern molecular techniques and research into virology, immunology, and pathogenesis enable the design of safe and potent novel candidates, yet the live-attenuated approach seems to have gone out of fashion. Is there still a place for attenuated vaccines, or have other approaches, like mRNA, made them obsolete?

This Special Issue welcomes articles that probe various topics around live-attenuated vaccine candidates against important viral diseases. We welcome rational attenuation strategies, characterization of natural strain variation, efficacy and safety results in animal models and the clinic, studies of genetic stability, immunological correlates of protection, and comparative pathology. Additionally, we are interested in reports on reversion, shedding, or other topics with safety implications.

Let us make this Special Issue a thought-provoking forum on the possibilities and special considerations of this approach!





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)